Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Robeco Institutional Asset Management B.V.
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. cut its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating) by 15.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,450 shares of the biotechnology company's stock after selling 4,512 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Corcept Therapeutics were worth $626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
根據美國證券交易委員會(納斯達克)的最新披露，Robeco機構資產管理公司在第三季度將其持有的Corcept Treateutics Inc.(美國證券交易委員會：CORT-GET評級)的股票削減了15.6%。該公司在此期間出售了4,512股後，擁有24,450股這家生物技術公司的股票。截至最近提交給美國證券交易委員會(美國證券交易委員會)的文件，Robeco機構資產管理公司在Corcept Treateutics持有的股份價值626,000美元。
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in Corcept Therapeutics by 2.5% during the first quarter. BlackRock Inc. now owns 15,424,767 shares of the biotechnology company's stock valued at $347,366,000 after purchasing an additional 376,774 shares during the period. Renaissance Technologies LLC lifted its position in Corcept Therapeutics by 0.8% during the second quarter. Renaissance Technologies LLC now owns 7,833,871 shares of the biotechnology company's stock valued at $186,289,000 after purchasing an additional 63,355 shares during the period. Federated Hermes Inc. lifted its position in Corcept Therapeutics by 16.8% during the second quarter. Federated Hermes Inc. now owns 5,537,000 shares of the biotechnology company's stock valued at $131,670,000 after purchasing an additional 796,580 shares during the period. State Street Corp lifted its position in Corcept Therapeutics by 2.6% during the second quarter. State Street Corp now owns 3,499,446 shares of the biotechnology company's stock valued at $83,217,000 after purchasing an additional 89,888 shares during the period. Finally, Parallel Advisors LLC lifted its position in Corcept Therapeutics by 39.8% during the second quarter. Parallel Advisors LLC now owns 2,718,328 shares of the biotechnology company's stock valued at $64,642,000 after purchasing an additional 774,009 shares during the period. 80.08% of the stock is currently owned by institutional investors and hedge funds.
其他一些機構投資者和對衝基金最近也增持或減持了該業務的股份。貝萊德股份有限公司在第一季度將其在Corcept Treateutics的持倉提高了2.5%。貝萊德股份有限公司目前持有這家生物技術公司15,424,767股股票，價值347,366,000美元，在此期間又購買了376,774股。文藝復興技術有限責任公司在第二季度將其在Corcept治療公司的頭寸提高了0.8%。復興科技有限責任公司現在擁有這家生物技術公司7833,871股股票，價值186,289,000美元，在此期間又購買了63,355股。聯合愛馬仕公司在第二季度將其在Corcept Treateutics的頭寸提高了16.8%。聯合愛馬仕公司目前持有這家生物技術公司5,537,000股股票，價值131,670,000美元，在此期間又購買了796,580股。道富集團在第二季度將其在Corcept Treateutics的頭寸提高了2.6%。道富集團目前持有這家生物技術公司3,499,446股股票，價值83,217,000美元，在此期間又購買了89,888股。最後，Parly Advisors LLC在第二季度將其在Corcept Treateutics的地位提高了39.8%。在此期間，Parly Advisors LLC又購買了774,009股，現在擁有2,718,328股這家生物技術公司的股票，價值64,642,000美元。80.08%的股票目前由機構投資者和對衝基金持有。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of research firms recently issued reports on CORT. StockNews.com upgraded shares of Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, December 27th. HC Wainwright cut their price objective on shares of Corcept Therapeutics from $33.00 to $30.00 and set a "buy" rating for the company in a report on Friday, December 9th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $31.25.
一些研究公司最近發佈了關於CORT的報告。在12月27日(星期二)的一份研究報告中，StockNews.com將Corcept Treateutics的股票評級從“買入”上調至“強力買入”。HC Wainwright將Corcept治療公司的股票目標價從33.00美元下調至30.00美元，並在12月9日星期五的一份報告中為該公司設定了“買入”評級。一位分析師對該股的評級為持有，三位分析師給出了買入評級，一位分析師給出了強烈的買入評級。根據MarketBeat.com的數據，該股目前的共識評級為買入，共識目標價為31.25美元。
Insider Transactions at Corcept Therapeutics
Corcept治療公司的內幕交易
Corcept Therapeutics Stock Performance
Corcept Treateutics股票業績
CORT opened at $22.44 on Friday. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of 22.44 and a beta of 0.60. The company has a fifty day moving average of $22.87 and a two-hundred day moving average of $25.49. Corcept Therapeutics Incorporated has a fifty-two week low of $16.47 and a fifty-two week high of $30.14.
Cort上週五開盤報22.44美元。該股市值24.2億美元，市盈率22.44倍，貝塔係數0.60。該公司的50日移動均線切入位在22.87美元，200日移動均線切入位在25.49美元。Corcept Treateutics Inc.的股價為52周低點16.47美元，52周高點為30.14美元。
Corcept Therapeutics (NASDAQ:CORT – Get Rating) last released its earnings results on Thursday, November 3rd. The biotechnology company reported $0.30 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.07. The business had revenue of $101.73 million during the quarter, compared to analysts' expectations of $107.73 million. Corcept Therapeutics had a net margin of 29.37% and a return on equity of 27.49%. On average, equities research analysts forecast that Corcept Therapeutics Incorporated will post 0.89 earnings per share for the current year.
科塞特治療公司(納斯達克代碼：CORT-GET評級)最近一次公佈財報是在11月3日星期四。這家生物技術公司公佈本季度每股收益為0.30美元，比分析師普遍預期的0.23美元高出0.07美元。該業務當季營收為1.0173億美元，高於分析師預期的1.0773億美元。Corcept Treeutics的淨利潤率為29.37%，股本回報率為27.49%。平均而言，股票研究分析師預測，Corcept治療公司本年度的每股收益將為0.89美元。
Corcept Therapeutics Profile
Corcept Treateutics簡介
(Get Rating)
(獲取評級)
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Corcept Treateutics公司在美國發現、開發和銷售治療嚴重代謝、腫瘤和神經精神疾病的藥物。該公司提供Korlym(米非司酮)片劑，作為每日一次的口服藥物，用於治療患有內源性庫欣綜合徵的成年患者繼發於高皮質醇血癥的高血糖，這些患者患有2型糖尿病或葡萄糖耐受不良，且手術失敗或不適合手術。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Corcept Therapeutics (CORT)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
- 免費獲取StockNews.com關於Corcept治療(CORT)的研究報告
- MarketBeat：回顧中的一週01/09-01/13
- 摩根大通破產，銀行為衰退做好準備
- 為什麼Bed Bath&Beyond的股價上漲了261%？
- Roku股價走勢，原因如下
- Carvana Stock Rally，這是你需要知道的
Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Rating).
想看看其他對衝基金持有Cort的股票嗎？訪問HoldingsChannel.com獲取Corcept Treateutics Inc.(納斯達克：CORT-GET Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Corcept治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Corcept Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。